ZA200105702B - Antiviral nucleoside analogues. - Google Patents
Antiviral nucleoside analogues. Download PDFInfo
- Publication number
- ZA200105702B ZA200105702B ZA200105702A ZA200105702A ZA200105702B ZA 200105702 B ZA200105702 B ZA 200105702B ZA 200105702 A ZA200105702 A ZA 200105702A ZA 200105702 A ZA200105702 A ZA 200105702A ZA 200105702 B ZA200105702 B ZA 200105702B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- compound according
- nucleoside
- treatment
- alkyl
- Prior art date
Links
- 229940127073 nucleoside analogue Drugs 0.000 title claims description 6
- 230000000840 anti-viral effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000002777 nucleoside Substances 0.000 claims description 12
- -1 C . Chemical group 0.000 claims description 11
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 229960005319 delavirdine Drugs 0.000 claims description 2
- 229960002656 didanosine Drugs 0.000 claims description 2
- 239000001177 diphosphate Chemical group 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229960003804 efavirenz Drugs 0.000 claims description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 2
- 229960001936 indinavir Drugs 0.000 claims description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000004712 monophosphates Chemical group 0.000 claims description 2
- 229960000884 nelfinavir Drugs 0.000 claims description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 2
- 229960000689 nevirapine Drugs 0.000 claims description 2
- 229960000311 ritonavir Drugs 0.000 claims description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 2
- 229960001852 saquinavir Drugs 0.000 claims description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 2
- 229960001203 stavudine Drugs 0.000 claims description 2
- 239000001226 triphosphate Chemical group 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical group OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000523 zalcitabine Drugs 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims 1
- 229940124821 NNRTIs Drugs 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 7
- 241000700721 Hepatitis B virus Species 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229950005339 lobucavir Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11379798P | 1998-12-23 | 1998-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105702B true ZA200105702B (en) | 2002-10-11 |
Family
ID=22351590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105702A ZA200105702B (en) | 1998-12-23 | 2001-07-11 | Antiviral nucleoside analogues. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US6358963B1 (ko) |
| EP (1) | EP1140937B1 (ko) |
| JP (1) | JP2002533470A (ko) |
| KR (1) | KR100653485B1 (ko) |
| CN (1) | CN1117751C (ko) |
| AP (1) | AP2001002207A0 (ko) |
| AT (1) | ATE254126T1 (ko) |
| AU (1) | AU760875B2 (ko) |
| BR (1) | BR9916849A (ko) |
| CA (1) | CA2355712C (ko) |
| CZ (1) | CZ20012352A3 (ko) |
| DE (1) | DE69912842T2 (ko) |
| DK (1) | DK1140937T3 (ko) |
| EA (1) | EA004767B1 (ko) |
| ES (1) | ES2209532T3 (ko) |
| HU (1) | HUP0104827A3 (ko) |
| ID (1) | ID30477A (ko) |
| IL (1) | IL143867A0 (ko) |
| MX (1) | MXPA01006425A (ko) |
| NO (1) | NO20013163L (ko) |
| NZ (1) | NZ513094A (ko) |
| OA (1) | OA11741A (ko) |
| PT (1) | PT1140937E (ko) |
| TR (1) | TR200102501T2 (ko) |
| UY (1) | UY25878A1 (ko) |
| WO (1) | WO2000039143A2 (ko) |
| ZA (1) | ZA200105702B (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002533470A (ja) * | 1998-12-23 | 2002-10-08 | シャイアー・バイオケム・インコーポレイテッド | 抗ウイルス性ヌクレオシド類似体 |
| ATE360016T1 (de) * | 2000-02-11 | 2007-05-15 | Shire Biochem Inc | Ein stereoselektives verfahren zur herstellung von nukleosidanalogen |
| WO2004009595A1 (en) * | 2002-07-03 | 2004-01-29 | Triangle Pharmaceuticals, Inc. | Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors |
| MXPA05001451A (es) | 2002-08-06 | 2005-09-30 | Pharmasset Ltd | Procesos para preparar nucleosidos de 1,3-dioxolano. |
| US7706405B2 (en) * | 2002-09-12 | 2010-04-27 | Interdigital Technology Corporation | System for efficient recovery of Node-B buffered data following MAC layer reset |
| EP1573019B1 (en) * | 2002-11-18 | 2009-01-14 | Shire BioChem Inc. | Stereoselective process for the production of dioxolane nucleoside analogues |
| DE10335061B4 (de) * | 2003-07-31 | 2005-11-17 | Wacker-Chemie Gmbh | Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten |
| US7785839B2 (en) | 2004-02-03 | 2010-08-31 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
| US7322412B2 (en) * | 2004-08-30 | 2008-01-29 | Halliburton Energy Services, Inc. | Casing shoes and methods of reverse-circulation cementing of casing |
| ATE516249T1 (de) * | 2008-03-20 | 2011-07-15 | Befesa Salzschlacke Gmbh | Hochtonerdehaltiger rohstoff und verfahren zur herstellung |
| WO2012048455A1 (zh) * | 2010-10-12 | 2012-04-19 | 武汉大学 | 一种抗病毒透皮吸收贴片及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000137A (en) | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
| US4041037A (en) | 1975-06-10 | 1977-08-09 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized cytidine |
| JPS5668674A (en) | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
| JPS5738774A (en) | 1980-08-19 | 1982-03-03 | Chugai Pharmaceut Co Ltd | Uracil derivative and its preparation |
| US4479942A (en) | 1981-08-10 | 1984-10-30 | Fujisawa Pharmaceutical Co., Ltd. | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof |
| IL86007A0 (en) * | 1987-04-09 | 1988-09-30 | Wellcome Found | 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them |
| HU198933B (en) | 1987-11-02 | 1989-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new xanthine derivatives and pharmaceutical compositions comprising same as active ingredient |
| US5270315A (en) | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
| US5041449A (en) | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
| NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US4987224A (en) | 1988-08-02 | 1991-01-22 | University Of Georgia Research Foundation, Inc. | Method of preparation of 2',3'-dideoxynucleosides |
| PT674634E (pt) | 1989-02-08 | 2003-09-30 | Iaf Biochem Int | Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais |
| PT95516A (pt) * | 1989-10-06 | 1991-08-14 | Wellcome Found | Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5276151A (en) | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
| US5700937A (en) | 1990-02-01 | 1997-12-23 | Emory University | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| DK0560794T3 (da) | 1990-11-13 | 1996-12-23 | Iaf Biochem Int | Substituerede 1,3-oxathiolaner med antivirale egenskaber |
| US5179104A (en) | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
| WO1992010496A1 (en) | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
| US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
| US5444063A (en) | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| NZ241625A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| GB9109506D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Therapeutic nucleosides |
| GB9110874D0 (en) | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| GB9200150D0 (en) | 1992-01-06 | 1992-02-26 | Wellcome Found | Therapeutic nucleosides |
| US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
| GB9525606D0 (en) | 1995-12-14 | 1996-02-14 | Iaf Biochem Int | Method and compositions for the synthesis of dioxolane nucleosides with - configuration |
| US5792773A (en) | 1996-11-15 | 1998-08-11 | Yale University | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection |
| JP2002533470A (ja) * | 1998-12-23 | 2002-10-08 | シャイアー・バイオケム・インコーポレイテッド | 抗ウイルス性ヌクレオシド類似体 |
-
1999
- 1999-12-22 JP JP2000591054A patent/JP2002533470A/ja active Pending
- 1999-12-22 KR KR1020017008068A patent/KR100653485B1/ko not_active IP Right Cessation
- 1999-12-22 AU AU17657/00A patent/AU760875B2/en not_active Ceased
- 1999-12-22 PT PT99960757T patent/PT1140937E/pt unknown
- 1999-12-22 CN CN99816209A patent/CN1117751C/zh not_active Expired - Fee Related
- 1999-12-22 DK DK99960757T patent/DK1140937T3/da active
- 1999-12-22 ES ES99960757T patent/ES2209532T3/es not_active Expired - Lifetime
- 1999-12-22 DE DE69912842T patent/DE69912842T2/de not_active Expired - Lifetime
- 1999-12-22 IL IL14386799A patent/IL143867A0/xx unknown
- 1999-12-22 CZ CZ20012352A patent/CZ20012352A3/cs unknown
- 1999-12-22 OA OA1200100171A patent/OA11741A/en unknown
- 1999-12-22 CA CA002355712A patent/CA2355712C/en not_active Expired - Fee Related
- 1999-12-22 EA EA200100711A patent/EA004767B1/ru not_active IP Right Cessation
- 1999-12-22 ID IDW00200101622A patent/ID30477A/id unknown
- 1999-12-22 US US09/468,813 patent/US6358963B1/en not_active Expired - Fee Related
- 1999-12-22 TR TR2001/02501T patent/TR200102501T2/xx unknown
- 1999-12-22 WO PCT/CA1999/001229 patent/WO2000039143A2/en active IP Right Grant
- 1999-12-22 HU HU0104827A patent/HUP0104827A3/hu unknown
- 1999-12-22 MX MXPA01006425A patent/MXPA01006425A/es not_active Application Discontinuation
- 1999-12-22 AP APAP/P/2001/002207A patent/AP2001002207A0/en unknown
- 1999-12-22 EP EP99960757A patent/EP1140937B1/en not_active Expired - Lifetime
- 1999-12-22 AT AT99960757T patent/ATE254126T1/de not_active IP Right Cessation
- 1999-12-22 NZ NZ513094A patent/NZ513094A/en unknown
- 1999-12-22 BR BR9916849-9A patent/BR9916849A/pt not_active IP Right Cessation
- 1999-12-23 UY UY25878A patent/UY25878A1/es unknown
-
2001
- 2001-06-22 NO NO20013163A patent/NO20013163L/no not_active Application Discontinuation
- 2001-06-29 US US09/893,605 patent/US6545001B2/en not_active Expired - Fee Related
- 2001-07-11 ZA ZA200105702A patent/ZA200105702B/en unknown
-
2003
- 2003-02-28 US US10/375,121 patent/US20040058893A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9758489B2 (en) | Azepane derivatives and methods of treating hepatitis B infections | |
| US9126971B2 (en) | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | |
| US20040229839A1 (en) | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | |
| ES2244204T3 (es) | Derivados de dicetoacidos como inhibidores de polimerasas. | |
| JP2011511802A (ja) | Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法 | |
| EP1835916B1 (en) | Compounds useful in the treatment of hiv | |
| US20150274652A1 (en) | Piperidine derivatives and methods of treating hepatitis b infections | |
| AU2016231615A1 (en) | Hepatitis B antiviral agents | |
| JP2017504626A (ja) | Ｂ型肝炎感染症を治療するアゼパン誘導体及び方法 | |
| CN101443007A (zh) | Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途 | |
| JP2006524711A5 (ko) | ||
| ZA200105702B (en) | Antiviral nucleoside analogues. | |
| US20040138170A1 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
| WO2016012913A1 (en) | Phenyl and tertbutylacetic acid substituted pyridinones having anti-hiv effects | |
| JP4887305B2 (ja) | Ｈｉｖの治療に有用な化合物 | |
| EP1063888A1 (en) | Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors | |
| JP2008526713A5 (ko) | ||
| JP2002533470A5 (ko) | ||
| JP2020505437A (ja) | 神経変性疾患の治療のための中性スフィンゴミエリナーゼ２（ｎＳＭａｓｅ２）の小分子阻害剤 | |
| KR19980701856A (ko) | 사람 면역결핍 바이러스 프로테아제 억제제인 인디나비르 및 역전사효소 억제제인 β-Ｌ-2',3'-디데옥시-3'-티아사이티딘, 및 임의의 지도부딘, 디데옥시이노신 또는 디데옥시사이티딘을 사용한 사람 면역결핍 바이러스 감염의 배합 치료 | |
| JPH0352816A (ja) | 腎炎の治療剤 | |
| JP2014532636A (ja) | ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法 | |
| US20090247557A1 (en) | Partial and full agonists of a1 adenosine receptors | |
| Nikolopoulos et al. | Antiretrovirals for HIV exposure prophylaxis | |
| US20050049242A1 (en) | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors |